Jennifer Leigh

Dr. Jennifer Leigh

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JLJennifer Leigh
Jennifer Leigh
BSBecky Skidmore
Becky Skidmore
AWAdrian Wong
Adrian Wong
SVSaman Maleki Vareki
Saman Maleki Vareki
Terry NgTerry Ng
Terry Ng
Background: The human microbiome plays a crucial role in health and disease. Dysbiosis, an imbalance of microorganisms, has been implicated in cancer development and treatment response, including in primary brain tumors and brain metastases, through interactions mediated by the gut–brain axis. This scoping review synthesizes current evidence on the relationship between the human microbiome and brain tumors. Methods: A systematic search of five electronic databases was conducted by an expert librarian, using controlled vocabulary and keywords. A targeted grey literature search in Google Scholar and clinical trial registries was also undertaken. Eligible studies included primary research involving human patients, or in vivo, or in vitro models of glioma or brain metastasis, with a focus on the microbiome’s role in tumor development, treatment response, and outcomes. Results: Out of 584 citations screened, 40 studies met inclusion criteria, comprising 24 articles and 16 conference abstracts. These included 12 human studies, 16 using mouse models, 7 combining both, and 5 employing large datasets or next-generation sequencing of tumor samples. Thirty-one studies focused on primary brain tumors, six on brain metastases, and three on both. Of the 20 studies examining dysbiosis in tumor development, 95% (n = 19) found an association with tumor growth. Additionally, 71.4% (n = 5/7) of studies reported that microbiome alterations influenced treatment efficacy. Conclusions: Although the role of the gut–brain axis in brain tumors is still emerging and is characterized by heterogeneity across studies, existing evidence consistently supports a relationship between the gut microbiome and both brain tumor development and treatment outcomes.

17 November 2022 in Cancer Medicine
Verified
Journal Article
Open access
JLJennifer Leigh
Jennifer Leigh
DQDanial Qureshi
Danial Qureshi
ESEwa Sucha
Ewa Sucha
RMRoshanak Mahdavi
Roshanak Mahdavi
IKIgal Kushnir
Igal Kushnir
MOMichael Ong
Michael Ong
IntroductionLife-prolonging therapies (LPTs) are rapidly evolving for the treatment of advanced prostate cancer, although factors associated with real-world uptake are not well characterized. MethodsIn this cohort of prostate-cancer decedents, we analyzed factors associated with LPT access. Population-level databases from Ontario, Canada identified patients 65 years or older with prostate cancer receiving androgen deprivation therapy and who died of prostate cancer between 2013 and 2017. Univariate and multivariable analyses assessed the association between baseline characteristics and receipt of LPT in the 2 years prior to death. ResultsOf 3575 patients who died of prostate cancer, 40.4% (n = 1443) received LPT, which comprised abiraterone (66.3%), docetaxel (50.3%), enzalutamide (17.2%), radium-223 (10.0%), and/or cabazitaxel (3.5%). Use of LPT increased by year of death (2013: 22.7%, 2014: 31.8%, 2015: 41.8%, 2016: 49.1%, and 2017: 57.9%, p < 0.0001), driven by uptake of all agents except docetaxel. Adjusted odds of use were higher for patients seen at Regional Cancer Centers (OR: 1.8, 95% CI: 1.5-2.1) and who received prior prostate-directed therapy (OR: 1.3, 95% CI: 1.0-1.5), but lower with advanced age (>= 85: OR: 0.54, 95% CI:0.39-0.75), increased chronic conditions (>= 6: OR: 0.62, 95% CI: 0.43-0.92), and long-term care residency (OR: 0.38, 95% CI: 0.17-0.89). Income, stage at presentation, and distance to the cancer center were not associated with LPT uptake. ConclusionIn this cohort of prostate cancer-decedents, real-world uptake of novel prostate cancer therapies occurred at substantially higher rates for patients receiving care at Regional Cancer Centers, reinforcing the potential benefits for treatment access for patients referred to specialist centers.

27 December 2025 in eClinicalMedicine
Verified
Journal Article
Open access
JJJason Li Jia
Jason Li Jia
BABader Alshamsan
Bader Alshamsan
ABAna Beltran-Bless
Ana Beltran-Bless
MMMegan MacRae
Megan MacRae
FRFoster Rose
Foster Rose
Terry NgTerry Ng
Terry Ng
Routine antibiotic prophylaxis against pneumocystis jirovecii pneumonia (PJP) is recommended during concurrent temozolomide and radiotherapy (TMZ-RT) for glioma based on early small studies. However, true PJP risk may be far lower, raising questions about the value and harms of universal prophylaxis. We conducted a systematic review (PROSPERO: CRD42021292396) of studies reporting PJP incidence among glioma patients treated with TMZ-RT. MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to May 1, 2025. Outcomes included overall PJP incidence and rates stratified by prophylaxis, corticosteroid exposure, and lymphopenia. Of 3791 records, 35 studies (13,637 patients, 12,301 received TMZ-RT) met eligibility criteria. Across 24 studies confirming PJP, 71 cases occurred among 12,056 TMZ-RT patients—a pooled incidence of 0.74% (95% CI, 0.59–0.93%) with minimal heterogeneity (Q = 23.3, p = 0.44; I2 = 1.4%). Seventeen studies detailed prophylaxis: 55.1% (2942/5341) of patients received it; PJP incidence was 0.8% (14/1765) with versus 0.3% (9/2719) without prophylaxis. Baseline corticosteroid exposure was reported in 13 studies (n = 5908: median 49.5%, range 27.3%–82.3%), and grade 3–4 lymphopenia in 15.2% (319/2102) of TMZ-RT patients. Incomplete study-level reporting precluded robust risk factor-adjusted analyses. Across heterogeneous populations and study designs, the pooled PJP incidence associated with TMZ-RT was 0.74% (95% CI, 0.59–0.93%). Due to the heterogeneity in study populations and designs, lack of standardized diagnostic confirmation, and incomplete reporting of steroid administration, this finding should be interpreted with caution. Currently available evidence suggests the risk of PJP is lower than the commonly cited 3.5% threshold for prophylaxis. Well-designed prospective studies are needed to clarify true infection risk and inform prophylaxis decisions. The Deanship of Graduate Studies and Scientific Research at 10.13039/501100007414 Qassim University provided financial support for the article processing charge (APC) of this manuscript.

18 March 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
JLJennifer Leigh
Jennifer Leigh
AAArwa Ahmed
Arwa Ahmed
FAFrancine Aubin
Francine Aubin
SBScott Berry
Scott Berry
MBMelanie Boucher
Melanie Boucher
Michael VickersMichael Vickers
Michael Vickers
The Eastern Canadian Gastrointestinal Cancer Consensus Conference was an annual meeting that was held in St. John’s, Newfoundland and Labrador, from 26 to 28 September 2024. This included experts in medical oncology, radiation oncology, surgical oncology, nuclear medicine, and general practitioners in oncology (GPO) from across the eastern Canadian provinces who are involved in the management of patients with gastrointestinal malignancies. This consensus statement generated by the conference addresses multiple topics, including the management of localized rectal cancer, liver-limited colorectal cancer, systemic therapy for advanced biliary tract cancers, radioligand therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), systemic therapy for pancreatic and midgut well-differentiated NETs, and systemic therapy for HER2-positive gastroesophageal cancers.

19 October 2026 in Current Opinion in Supportive & Palliative Care
Verified
Journal Article
Closed access
RLRachel Leong
Rachel Leong
EMEmily MacMillan
Emily MacMillan
CYChristina Yang
Christina Yang
JSJapyjot Singh
Japyjot Singh
JCJefferson Chan
Jefferson Chan
JLJennifer Leigh
Jennifer Leigh
Purpose: Treatment-related nausea and vomiting (TRNV) is among the most distressing and commonly reported adverse effects of antineoplastic therapy and can significantly impair patients’ quality of life (QoL). This review summarizes the evidence on how TRNV affects QoL across cancer types, treatment regimens, antiemetic strategies, and phases of TRNV. Recent findings: TRNV negatively affects all domains of QoL in patients with cancer, particularly physical and functional well-being. Studies consistently reported worsened fatigue, insomnia, appetite loss, pain, impaired activities of daily living, meal enjoyment, and role functioning. Psycho-social and cognitive effects were also observed, although findings were more variable. Despite advances in antiemetic interventions and supportive strategies, patients continued to experience a substantial symptom burden and worsened QoL following treatment. Most studies explored chemotherapy-related TRNV and did not focus on a specific cancer type. A wide range of QoL instruments were used, but no single tool comprehensively assessed all QoL domains while remaining specific to cancer-related nausea and vomiting. Summary: TRNV is associated with a significant decline in QoL among patients with cancer. Further research on QoL after TRNV within specific cancer types and treatment modalities and the development of a more comprehensive QoL tool are needed to improve cross-study comparability and to better understand patient outcomes.

11 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JLJennifer Leigh
Jennifer Leigh
CTChristopher F. Theriau
Christopher F. Theriau
BABader Alshamsan
Bader Alshamsan
JRJessica Rodrigues
Jessica Rodrigues
JJJason Jia
Jason Jia
TNTerry L. Ng
Terry L. Ng
Introduction: Trastuzumab deruxtecan (T-DXd) is associated with chemotherapy-induced nausea and vomiting (CINV), yet the incidence, severity, and optimal antiemetic prophylaxis remain uncertain. We conducted a systematic review and meta-analysis to quantify T-DXd–related nausea and vomiting and evaluate the effectiveness of triplet vs doublet prophylaxis.Methods: Following PRISMA guidelines, we searched Ovid MEDLINE® ALL, Embase, and the Cochrane Library (1946 to June 2025) for studies reporting nausea and vomiting outcomes with T-DXd. Random-effects meta-analyses were used to estimate pooled incidence by dose level, risk ratios (RRs) with 95% confidence intervals (CIs), and between-study heterogeneity. The primary endpoint was pooled incidence of nausea and vomiting. Secondary endpoints included relative risk compared with standard therapies and comparative effectiveness of triplet vs doublet antiemetic prophylaxis.Results: Thirty-two studies including 5,365 patients (4,224 T-DXd recipients) met inclusion. At the approved 5.4 mg/kg dose, pooled incidence was 65% for any-grade nausea and 31% for any-grade vomiting, with ≥ grade 3 events ≤4%. Incidence rates were similar at 6.4 mg/kg, with no significant dose-dependent increase in gastrointestinal toxicity (RR 0.96; 95% CI 0.83–1.11). Across five randomized trials, T-DXd significantly increased the risk of any-grade nausea 70.8% vs 28.4% (RR 2.29; 95% CI 1.74–3.02) and vomiting (RR 3.49; 95% CI 2.78–4.38) compared with standard therapies, while high-grade events remained uncommon (≤4%). Triplet antiemetic prophylaxis significantly improved delayed-phase nausea control (e.g., delayed complete response: RR 1.27; 95% CI 1.03–1.58) but did not confer additional benefit in the acute phase. No statistically significant differences were observed between NK1 receptor antagonist–based and olanzapine-based triplets.Conclusion: Nausea and vomiting, particularly delayed nausea, are common with T-DXd, representing a major unmet supportive-care need. Triplet antiemetic prophylaxis improves delayed nausea control and should be considered. Future prospective studies incorporating patient-reported outcomes are needed to optimize prophylactic strategies.